NasdaqGS - Nasdaq Real Time Price USD
Elevation Oncology, Inc. (ELEV)
As of 11:22 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.2 | -0.21 | -0.82 | -0.88 |
| Low Estimate | -0.21 | -0.24 | -0.9 | -1.07 |
| High Estimate | -0.19 | -0.19 | -0.77 | -0.64 |
| Year Ago EPS | -0.25 | -0.19 | -1.34 | -0.82 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.32 | -0.24 | -0.2 | -0.22 |
| EPS Actual | -0.25 | -0.19 | -0.23 | -0.18 |
| Difference | 0.07 | 0.05 | -0.03 | 0.04 |
| Surprise % | 21.90% | 20.80% | -15.00% | 18.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.2 | -0.21 | -0.82 | -0.88 |
| 7 Days Ago | -0.2 | -0.21 | -0.82 | -0.88 |
| 30 Days Ago | -0.2 | -0.21 | -0.82 | -0.88 |
| 60 Days Ago | -0.2 | -0.21 | -0.82 | -0.88 |
| 90 Days Ago | -0.22 | -0.24 | -0.91 | -0.97 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ELEV | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 20.00% | -- | -- | 5.10% |
| Next Qtr. | -10.50% | -- | -- | 11.80% |
| Current Year | 38.80% | -- | -- | 2.10% |
| Next Year | -7.30% | -- | -- | 12.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.68% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/7/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 7/15/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 6/28/2024 |
| Initiated | Piper Sandler: Overweight | 5/31/2024 |
| Initiated | Stephens & Co.: Overweight | 5/14/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 5/3/2024 |
Related Tickers
INAB IN8bio, Inc.
0.2948
+5.21%
UNCY Unicycive Therapeutics, Inc.
0.5066
-5.39%
VINC Vincerx Pharma, Inc.
0.3588
+2.81%
VOR Vor Biopharma Inc.
0.8304
-1.12%
DRMA Dermata Therapeutics, Inc.
1.3100
+3.15%
IKNA Ikena Oncology, Inc.
1.7500
+2.34%
RNAZ TransCode Therapeutics, Inc.
0.4757
+2.30%
BCTX BriaCell Therapeutics Corp.
0.7870
-2.25%
CTMX CytomX Therapeutics, Inc.
1.0000
+0.43%
XLO Xilio Therapeutics, Inc.
1.2200
-3.97%